Reactive compounds and in vitro false positives in HTS

An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 1997-09, Vol.2 (9), p.382-384
Main Author: Rishton, Gilbert M.
Format: Article
Language:English
Subjects:
Biological and medical sciences
General pharmacology
Medical sciences
Pharmacology. Drug treatments
Physicochemical properties. Structure-activity relationships
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An important component of the successful highthroughput screening (HTS) strategy in drug discovery is the ability to assess HTS structure-activity data, and to distinguish between promising drug leads and the many useless false positives that can plague screening efforts. The author discusses simple chemistry guidelines for the evaluation of ‘positives’ in biochemical screens, with the aim of selecting stable, non-covalent binders (ligands) and eliminating protein-reactive compounds (reagents) from consideration as drug leads at an early stage.
ISSN:1359-6446
1878-5832
DOI:10.1016/S1359-6446(97)01083-0